MAP2K7 and neoplasm: Here, using a combination of transcriptomics, proteomics, multiplex spatial profiling as well as in vitro and in vivo functional assays, we show that JAK/STAT3 activity is upregulated following selumetinib treatment in SHH MB tumor xenografts and that targeting this pathway, in combination with MEK inhibition, significantly attenuates tumor growth.